CR20200082A - Virus chikungunya inmunogénico - Google Patents

Virus chikungunya inmunogénico

Info

Publication number
CR20200082A
CR20200082A CR20200082A CR20200082A CR20200082A CR 20200082 A CR20200082 A CR 20200082A CR 20200082 A CR20200082 A CR 20200082A CR 20200082 A CR20200082 A CR 20200082A CR 20200082 A CR20200082 A CR 20200082A
Authority
CR
Costa Rica
Prior art keywords
immunogenic
chikungunya virus
virus
producing
well
Prior art date
Application number
CR20200082A
Other languages
English (en)
Inventor
Andreas Meinke
Jürgen Heindl-Wruss
Robert Schlegl
Urban Lundberg
Mario Nebenführ
Andrea Fritzer
Arnaud Leon
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of CR20200082A publication Critical patent/CR20200082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a un proceso para producir un virus de Chikungunya atenuado vivo, inmunogénico, así como también composiciones farmacéuticas que comprenden el mismo.
CR20200082A 2017-09-21 2018-09-19 Virus chikungunya inmunogénico CR20200082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192374 2017-09-21
PCT/EP2018/075392 WO2019057793A1 (en) 2017-09-21 2018-09-19 PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3

Publications (1)

Publication Number Publication Date
CR20200082A true CR20200082A (es) 2020-05-17

Family

ID=59955395

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200082A CR20200082A (es) 2017-09-21 2018-09-19 Virus chikungunya inmunogénico

Country Status (15)

Country Link
US (4) US11484587B2 (es)
EP (1) EP3684404A1 (es)
JP (2) JP7301811B2 (es)
KR (1) KR102757369B1 (es)
CN (2) CN118662621A (es)
AR (1) AR113257A1 (es)
AU (1) AU2018337681B2 (es)
BR (1) BR112020003470B1 (es)
CA (1) CA3073234A1 (es)
CO (1) CO2020001927A2 (es)
CR (1) CR20200082A (es)
PH (1) PH12020500329A1 (es)
SG (1) SG11202001161YA (es)
TW (1) TWI803521B (es)
WO (1) WO2019057793A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4357355A3 (en) 2015-12-23 2024-09-25 Valneva SE Virus purification
KR102757369B1 (ko) 2017-09-21 2025-01-20 발네바 에스이 면역원성 치쿤구니야 바이러스 chikv-델타5nsp3을 포함하는 약제학적 조성물의 생산 방법
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
AU2020328159A1 (en) 2019-08-09 2022-01-27 Valneva Se Single shot Chikungunya virus vaccine
PH12021553186A1 (en) 2019-08-09 2022-12-12 Valneva Se Chikungunya vaccine formulations
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
IL296071A (en) 2020-03-01 2022-11-01 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US12605442B2 (en) 2020-03-06 2026-04-21 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
US20230174953A1 (en) * 2020-03-27 2023-06-08 Institut Pasteur Defective interfering viral genomes
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2024184473A1 (en) 2023-03-08 2024-09-12 Valneva Austria Gmbh Immunogenic chikungunya compositions for administration to immunocompromised patients
WO2026052882A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Yellow fever virus (yfv) compositions and production thereof
WO2026052881A1 (en) 2024-09-09 2026-03-12 Valneva Austria Gmbh Chikungunya virus vaccine multidose formulation and use thereof in outbreaks
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142271C (zh) 1997-08-28 2004-03-17 第一制糖株式会社 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗
AU2001275191A1 (en) 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002089840A1 (en) 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
WO2008030220A2 (en) * 2005-08-11 2008-03-13 The Board Of Regents Of The University Of Texas System Chikungunya virus infectious clones and uses thereof
CA2545597A1 (en) * 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
WO2009048633A2 (en) * 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
ES2588738T3 (es) * 2008-04-04 2016-11-04 The Trustees Of The University Of Pennsylvania Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas
SG171828A1 (en) 2008-11-26 2011-07-28 Us Gov Health & Human Serv Virus like particle compositions and methods of use
WO2010085358A2 (en) 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
WO2012078116A1 (en) * 2010-12-10 2012-06-14 Agency For Science, Technology And Research Immunogenic chikungunya virus peptides
AU2012269907B2 (en) * 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
RS56709B1 (sr) 2011-12-06 2018-03-30 Valneva Austria Gmbh Jedinjenja aluminijuma za primenu u terapeuticima i vakcinama
US9701719B2 (en) * 2012-09-27 2017-07-11 Research Development Foundation Attenuated Chikungunya virus
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP4357355A3 (en) 2015-12-23 2024-09-25 Valneva SE Virus purification
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
KR102757369B1 (ko) * 2017-09-21 2025-01-20 발네바 에스이 면역원성 치쿤구니야 바이러스 chikv-델타5nsp3을 포함하는 약제학적 조성물의 생산 방법

Also Published As

Publication number Publication date
AU2018337681A1 (en) 2020-02-27
CA3073234A1 (en) 2019-03-28
US20220016230A1 (en) 2022-01-20
US20210322534A1 (en) 2021-10-21
EP3684404A1 (en) 2020-07-29
US12564625B2 (en) 2026-03-03
TWI803521B (zh) 2023-06-01
JP7738032B2 (ja) 2025-09-11
AR113257A1 (es) 2020-03-11
NZ761619A (en) 2024-03-22
BR112020003470A2 (pt) 2020-10-27
SG11202001161YA (en) 2020-03-30
TW201920663A (zh) 2019-06-01
KR102757369B1 (ko) 2025-01-20
JP2023116780A (ja) 2023-08-22
WO2019057793A1 (en) 2019-03-28
BR112020003470B1 (pt) 2023-09-26
CN111263642B (zh) 2024-06-21
JP2020534256A (ja) 2020-11-26
US20250073326A1 (en) 2025-03-06
PH12020500329A1 (en) 2020-10-05
CN111263642A (zh) 2020-06-09
NZ803766A (en) 2024-04-26
AU2018337681B2 (en) 2025-04-10
US12011477B2 (en) 2024-06-18
CN118662621A (zh) 2024-09-20
US11484587B2 (en) 2022-11-01
CO2020001927A2 (es) 2020-04-01
US20230293661A1 (en) 2023-09-21
US11357846B2 (en) 2022-06-14
KR20200056982A (ko) 2020-05-25
JP7301811B2 (ja) 2023-07-03

Similar Documents

Publication Publication Date Title
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
CL2018001230A1 (es) Tratamiento de osteoartritis
MX2021000174A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
UY35815A (es) ?locus óptimos del maíz?
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
PH12016502586A1 (en) Lipid comprising docosapentaenoic acid
MX2016014643A (es) Composiciones de insulina de rapida accion.
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
UA120058C2 (uk) Пестицидні композиції
MX2019009606A (es) Bis-compuestos para dispositivos opticamente activos.
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
MX2025012276A (es) Composiciones de methylobacterium para mejorar el rendimiento del maiz
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
TN2018000351A1 (en) Oxaborole esters and uses thereof
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX387903B (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
MX390480B (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
BR112016028192A2 (pt) gerritdina g. schoonus-gerritsma